Industry Sees Little Benefit Of New EU Clinical Trial Rules On Information Materials For Minors
Executive Summary
The European pharmaceutical industry trade group, EFPIA, is concerned about new requirements proposed in a draft European Commission guideline about how sponsors should prepare and test information materials used for obtaining informed consent from minors participating in clinical trials. It has, however, welcomed proposed changes on the use of a “staggered approach” to recruiting minors into trials.
You may also be interested in...
Final ICH Addendum Offers Latest Perspectives On Pediatric Drug Development
A new document that complements the International Council for Harmonisation's existing guideline on pediatric clinical trials is expected to reduce the likelihood of significant differences among countries on the acceptance of data generated in pediatric global drug development programs
New ICH Guideline Marks Turning Point In Supporting Multi-Regional Pediatric Development
A new high-level draft ICH guideline issued is expected to reduce the likelihood of substantial differences among regions regarding acceptance of data generated in pediatric global drug development.
Commission Consults On New Risk-Proportionate Approaches Under EU Clinical Trials Regulation
The European Commission is inviting stakeholder feedback on recommendations to help implement several key aspects of the new EU Clinical Trials Regulation, including how to apply a risk proportionate approach for the design and conduct of trials, and how to present a summary of clinical trial results to laypersons1.